Santalis, a TFC company, has reported positive test results for treating Ecezma in children. The following article contains the details. Interestingly, the article states the treatment should be ready for distribution in the marketplace by the start of 2017. It is very encouraging news.
http://www.businesswire.com/news/ho...is-Pharmaceuticals-Announces-Positive-Results